Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation

BayerBayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI). The company announced that new clinical data for gadoquatrane, Bayer's investigational macrocyclic gadolinium-based compound currently in Phase III development, will be presented at the 2023 Radiological Society of North America (RSNA) Annual Meeting - taking place from November 26 to 30, 2023, in Chicago, USA. Bayer also announced the results of a recently published paper on the cost effectiveness of supplemental screening methods for women with dense breasts in the U.S., to provide greater certainty around the clinical and economic benefits of supplemental screening methods. In addition, Bayer announced four collaboration agreements with the aim to further expand the offering on its medical imaging platform Calantic™ Digital Solutions.

The activities at RSNA reflect Bayer’s commitment as a leading company in key areas of radiology to address today’s industry challenges and accelerate innovation for the benefit of patients and their clinicians, including harnessing the vast potential of artificial intelligence (AI).

Fostering innovation in Radiology AI

In more than 30 panel discussions, Bayer's AI team composed jointly of experts from both Calantic™ Digital Solutions and Blackford Analysis as well as external thought leaders, will share insights to help healthcare providers, hospital administrators and developers advance their AI strategy, discussing topics like regulatory challenges in the field of AI in medical imaging, app selection, and how to leverage clinical utility frameworks to assess return on investment (ROI). Partner companies from both Bayer and Blackford will present various app approaches and solutions.

While Blackford provides infrastructure and access to a rich clinical application (ClinApp) ecosystem focused on imaging and analytics, Bayer’s own platform Calantic™ Digital Solutions which is building on technology from Blackford and adding additional workflow and analytics components, delivers access to applications for medical imaging, including those enabled by AI - coming with the value proposition to support diagnosis and increase the throughput of medical imaging examinations. On the occasion of RSNA 2023, Bayer also announced that it will partner with radiology AI technology providers Perspectum Limited, Brainomix Limited, Qure.ai, and Imagine Software - with the aim to further expand the offering on its medical imaging platform CalanticTM Digital Solutions.

In addition, Bayer is offering various tech talks, including pilot "Spark Tank Sessions" where app companies at an early stage can learn new ways to refine their value proposition, and get feedback such as optimal workflow and commercialization pathways from an expert panel. Calantic SPARK, Bayer’s accelerator program for medical imaging app developers to further foster innovation in radiology AI, will showcase its partners Imagine Software (Within Health) and Scanslated. Bayer's Calantic SPARK is a targeted program to help radiology AI startups of all stages get to market faster by offering advice spanning medical, regulatory, reimbursement expertise, and market access - thereby enabling commercialization and distribution through Calantic™ Digital Solutions.

Blackford, the global strategic AI platform and solutions provider that was acquired by Bayer under the well-established company’s arm’s length model, continues to expand its AI portfolio and global strategic relationships in advance of RSNA. The AI portfolio available via the Blackford Platform now includes over 100 applications from 40 separate partner vendors. Blackford has also recently entered into partnerships with global medical imaging provider Philips, healthcare interoperability provider Rhapsody and enterprise imaging provider Mach7 to support their respective journeys into AI solution provision.

Taking a glimpse at a radiology clinic of the future

Reflecting Bayer's overall RSNA 2023 theme "Let's Envision the Future of Radiology", the Experience Center at Bayer’s main booth (#2519) will offer visitors an immersive tour through a radiology clinic of the future. Here they can discover the company's digital, integrated, disease-oriented solutions across the entire radiology workflow - through the eyes of a patient. The Experience Center includes 21 different stations along the journey, each with interactive content, including Augmented Reality (AR).

About Radiology at Bayer

As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence - from innovative products to high-quality services - to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by Artificial Intelligence (AI). Bayer's radiology products generated close to €2bn sales in 2022. Based on the company’s ambition to outperform the radiology market’s average annual growth rate of 5 percent by 2030, Bayer is highly committed to research and development, which includes leveraging AI and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction - from diagnosis to care.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

Most Popular Now

Deep Learning Model Helps Detect Lung Tu…

A new deep learning model shows promise in detecting and segmenting lung tumors, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA)...

One of the Largest Global Surveys of Soc…

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch...

New Study Reveals AI's Transformati…

Intensive care units (ICUs) face mounting pressure to effectively manage resources while delivering optimal patient care. Groundbreaking research published in the INFORMS journal Information Systems Research highlights how a novel...

Sam Neville Joins the Highland Marketing…

Leading chief nursing information officer Sam Neville is joining the Highland Marketing advisory board. Sam brings a passion for nursing and safety to the board, which debates the big issues...

New Biomarkers to Detect Colorectal Canc…

Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of Birmingham researchers to discover proteins that have strong predictive potential for colorectal cancer. In a...

AI Tool that may Assist Underserved Hosp…

As the fields of healthcare and technology increasingly evolve and intersect, researchers are collaborating on the best ways to use emerging technologies such as artificial intelligence (AI) to care for...

AI Model Identifies Potential Risk Genes…

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics models to Parkinson's disease. Researchers identified genetic factors in progression and FDA-approved drugs that can...

AI-Supported Breast Cancer Screening - N…

The new findings are published in The Lancet Digital Health. The initial results of the Mammography Screening with Artificial Intelligence (MASAI) study* - a randomised trial to evaluate whether AI...

AI Improves Personalized Cancer Treatmen…

Personalized medicine aims to tailor treatments to individual patients. Until now, this has been done using a small number of parameters to predict the course of a disease. However, these...

The Future of Healthcare is Digital

8 - 10 April 2025, Berlin, Germany. The Berlin Exhibition Centre will be all about digital health from 8 to 10 April 2025. DMEA, Europe's leading event for digital healthcare, organised...

DMEA nova Award: Looking for the Best Id…

8 - 10 April 2025, Berlin, Germany. Innovative startups from the digital health sector can now apply for the DMEA nova Award 2025. We are looking for the best idea or...

Testing AI with AI: Ensuring Effective A…

Using a pioneering artificial intelligence platform, Flinders University researchers have assessed whether a cardiac AI tool recently trialled in South Australian hospitals actually has the potential to assist doctors and...